- Home
- SD vs OVID Comparison
SD vs OVID Comparison
Compare SD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | OVID |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 562.5M |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SD | OVID |
|---|---|---|
| Price | $14.63 | $2.69 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $15.00 | $4.60 |
| AVG Volume (30 Days) | 251.6K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | 3.90 |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | $19.34 |
| P/E Ratio | $12.05 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $11.10 | $1.12 |
| 52 Week High | $18.45 | $3.11 |
Technical Indicators
Market Signals| Indicator | SD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 46.31 |
| Support Level | $14.37 | $2.60 |
| Resistance Level | $15.71 | $2.77 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 71.14 | 10.29 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.